ANN ARBOR, MI — Oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) gained Food and Drug Administration approval in 2012, and many commentators hailed the therapy as a “once-in-a-generation” advance.
HOUSTON — After a decade of dramatically rising rates of hepatocellular carcinoma (HCC) among veterans, aggressive treatment of hepatitis C infections (HCV) appears poised to turn the tide.
Pre-infection Immunological Health Achieved in Some Cases By Annette M. Boyle SAN ANTONIO — For years, clinicians have not recommended treating human immunodeficiency virus (HIV) patients with antiretroviral therapy (ART) before they saw a significant drop in T-cell levels. Starting… Read More
VA Researchers Recommend Against the Practice in Most Cases By Brenda L. Mooney ANN ARBOR, MI — In a case where the preventive measure might be worse than the avoided outcome, hospitals at the VHA and elsewhere often routinely provide… Read More
New Research Uncovers Some Clues to Aid Prevention By Brenda L. Mooney WASHINGTON — As the VHA works to reduce the overall post-operative rate of Clostridium difficile infection (CDI), important new research has uncovered some clues to the circumstances that… Read More
For the VA, the combination of effective treatment options and much lower prevalence of HCV in younger veterans may offer a light at the end of the tunnel — and a turning point in the steady rise of HCV-associated complications such as cirrhosis and hepatocellular carcinoma (HCC) in only a few years.
Subhead: Post-operative Mortality Rates Low Among ART Users By Annette M. Boyle WEST HAVEN, CT — Historically, high post-operative mortality rates among HIV-infected patients caused many physicians and patients to defer or avoid surgery all together. For today’s veterans with… Read More
By Brenda L. Mooney SALT LAKE CITY — A study conducted in the VA health system uncovered a disturbing truth about overuse of antibiotics: A big contributor to the problem is that some clinicians prescribe the drugs to nearly every… Read More
The VA’s methicillin-resistant Staphylococcus aureus (MRSA) prevention initiative reduced healthcare-associated MRSA infections 69% in VA acute care facilities and 81% in spinal cord injury units in five years. The VA hopes to see similar success in preventing infections with Clostridium difficile (CDI) and carbapenem-resistant Enterobacteriaceae (CRE) — and the MRSA bundle itself may help them do that.
Lower immunization rates have increased the number of U.S. outbreaks of vaccine-preventable diseases, even of those considered eradicated in this country, such as measles.
Research Contradicts Other Recent Findings By Brenda L. Mooney PHILADELPHIA — As the latest influenza season finally abates, a new VA study raises questions about how effective the high-dose vaccine really is for the 65 or older cohort. Beginning at… Read More
Amid all the outcry over the high cost of new hepatitis C therapies, including congressional hearings, a simple fact has been overlooked: The VA expects to save money in the long run because of the drugs’ high cure rates. By… Read More
By Brenda L. Mooney BOSTON – Rates of serologic testing for hepatitis B (HBV) at the VA fail to meet levels recommended by the American Association for the Study of Liver Diseases (AASLD) practice guideline, according to new research. Researchers… Read More
Higher Pneumonia Vaccine Rates Urged By Brenda L. Mooney PROVIDENCE, RI – With influenza season each year comes an even greater challenge for VA hospitals — a spate of pneumonia cases in older veterans. Recent research suggests the problem will… Read More